Abstract. The oncogene B-cell-specific Moloney murine leukemia virus insertion site-1 (Bmi-1) is overexpressed in multiple myeloma (MM). Our previous study demonstrated that Bmi-1 silencing sensitized MM cells to bortezomib. Translational regulation has emerged as a prominent underlying mechanism of Bmi-1 regulation, particularly via microRNA targeting. The present study determined that Bmi-1 may be directly targeted by miR-203 using a luciferase assay. In addition, enforced expression of miR-203 led to significant downregulation of Bmi-1 protein and mRNA expression levels. Furthermore, restoration of miR-203 significantly inhibited cell growth and G 1 /S transition in MM cells. miR-203 was downregulated in MM patients, and a negative correlation between the expression of miR-203 and Bmi-1 was observed. The results of the present study indicated that miR-203 exerts growth-inhibiting effects in MM through the suppression of Bmi-1 expression. In conclusion, the present study demonstrated that Bmi-1 is a direct functional target of miR-203 in MM.
Introduction
B-cell-specific Moloney murine leukemia virus insertion site-1 (Bmi-1), a member of the polycomb family, was originally described as interacting with c-Myc to initiate lymphoma in mice (1) . Evidence suggests that Bmi-1 is critical for numerous physiological and pathological processes, including axial patterning (2) , hematopoiesis (3), regulation of proliferation, senescence (4) and self-renewal of cancer stem cells (5) . In addition, Bmi-1 is overexpressed in various malignancies (6) (7) (8) , including multiple myeloma (MM) (9) , and may regulate proliferation and carcinogenesis. Furthermore, our previous study demonstrated that silencing of Bmi-1 sensitizes MM cells to bortezomib (10) . Bmi-1 may be post-transcriptionally regulated by microRNAs (miRNAs) (11) (12) (13) (14) ; however, whether miRNAs target Bmi-1 in MM remains unclear.
miRNAs are endogenous non-coding small RNAs that post-transcriptionally regulate gene expression. They exert this effect by binding to the 3'untranslated regions (UTRs) of target mRNAs, resulting in degradation or repression of translation of mRNAs. miRNAs may function as oncogenes or tumor suppressor genes in human cancer (15) . Studies have suggested that numerous cancer-associated miRNAs are located in genomic breakpoint regions (16) . Certain miRNAs may be epigenetically inactivated, particularly by hypermethylation, and re-expression of these miRNAs may result in the downregulation of target oncogenes (17) . Hypermethylation of miR-203 in chronic myeloid leukemia (CML) (18) , hepatocellular carcinoma (19) and MM (20) has been described. Restoration of miR-203 downregulates the oncogenic BCR-ABL1 fusion protein and cyclic AMP responsive element binding protein 1 (CREB1) in CML and MM, respectively, thereby inhibiting cellular proliferation and demonstrating the tumor suppressor activity of miR-203. Computational analysis indicates that a single mRNA molecule may be regulated by multiple miRNAs and that one miRNA may regulate multiple mRNAs (21) . Therefore, miR-203 may target mRNAs other than CREB1 in MM.
The present study used bioinformatics databases, TargetScan, PicTar and miRanda, to predict the potential miRNAs that may target Bmi-1. A luciferase reporter assay was performed to determine that miR-203 directly targets the 3'UTRs of Bmi-1. Enforced expression of miR-203 significantly inhibits cell growth and regulates G 1 /S transition in MM cells. miR-203 was downregulated in MM and the expression of miR-203 was negatively correlated with Bmi-1 expression. Taken together, these results indicated that Bmi-1 is a critical target of the tumor suppressor activity of miR-203 in MM. O (7 µl). The PCR cycling conditions were as follows: Denaturation at 95˚C for 10 min, followed by 50 cycles of denaturation at 95˚C for 15 sec and annealing at 60˚C for 1 min. RNU6B served as an endogenous housekeeping control for data normalization of miR levels. mRNA was reverse-transcribed in RT reactions containing 500 ng total RNA extracted from samples, 2 µl 5X PrimeScript™ Buffer (Takara Bio, Inc., Otsu, Japan), 0.5 µl 1X PrimeScript™ RT Enzyme Mix I (Takara Bio, Inc.) and 0.5 µl oligo (dT) primer. The 10-µl reactions were incu bated for 42 min at 37˚C, followed by 30 sec at 85˚C and subsequent exposure to 4˚C. The endogenous mRNA levels of Bmi-1 were detected using the SYBR ® Green PCR Master mix kit (Takara Bio, Inc.), according to the manufacturer's protocol. The PCR cycling conditions were as follows: An initial denaturation step at 95˚C for 15 min, followed by 40 cycles of denaturation at 94˚C for 15 sec, annealing at 55˚C for 30 sec and extension at 72˚C for 30 sec. β-actin served as an internal control. The following primers (Invi trogen; Thermo Fisher Scientific, Inc.) were used: Forward, 5'-AAA TCA GGG GGT TGA AAA ATCT-3' and reverse, 5'-GCT AAC CAC CAA TCT TCC TTTG-3' for Bmi-1; and forward, 5'-TTG TTA CAG GAA GTC CCT TGCC-3' and reverse, 5'-ATG CTA TCA CCT CCC CTG TGTG-3' for β-actin. The comparative quantification cycle (Cq) method was used to measure the relative changes in expression; 2 -ΔΔCq represents the fold-change in expression (23) .
Materials and methods

Patient
Cell culture. HEK-293T cells were cultured in Dulbecco's modified Eagle's medium (Invit rogen; Thermo Fisher Scientific, Inc.) with 10% fetal bovine serum (FBS; Invitrogen; Thermo Fisher Scientific, Inc.). U266 and RPMI8226 cells were obtained from the American Type Culture Collection (Manassas, VA, USA) and cultured in RPMI 1640 medium (Invitrogen; Thermo Fisher Scientific, Inc.) with 10% FBS, 50 U/ml penicillin and 50 µg/ml streptomycin.
Lentivirus production and infection. The pri-miR-203 sequence was amplified and cloned into the pWPXL lentiviral vector (donated by Dr Didier Trono, École Polytechnique Fédérale de Lausanne, Lausanne, Switzerland). The primers were as follows: Forward, 5'-GAA TTC CGT CTA AGG CGT CCG GTA-3' and reverse, 5'-GCG GCC GCG TTC CCA CAG CAC AGC-3'. The pWPXL vectors were transfected into HEK-293T cells with the packaging plasmid psPAX2 and the VSV-G envelope plasmid pMD2.G (donated by Dr Didier Trono) using Lipofectamine ® 2000 reagent (Invitrogen; Thermo Fisher Scientific, Inc.). Cell superna tants were collected at 48 h post-transfection and passed through a 0.22-mm filter. The virus particles were harvested 48 h following transfection. The titer of purified virus was 2.0x108 IU/ml. Cells (1x10 5 ) were infected with 1x10 6 recombinant lentivirus-transducing units and 6 µg/ml Polybrene (Sigma-Aldrich; Merck Millipore, Darmstadt, Germany).
Cell proliferation. Cell proliferation was measured using the Cell Counting kit (CCK)-8 assay (Dojindo Molecular Technologies, Inc., Kumamoto, Japan). Cells were seeded into 96-well plates (4x10 3 /well), and 10 µl CCK-8 solution was added to 90 µl culture medium. Cells were subsequently incubated for 2 h at 37˚C and the optical density was measured at 450 nm and 650 nm. Three independent experiments were performed.
Cell cycle and apoptosis determination by flow cytometry. For cell cycle analysis, cells were collected and fixed in ice-cold 70% ethanol overnight. The fixed cells were washed with phosphate-buffered saline (PBS) and stained with freshly-prepared PBS containing 25 µg/ml propidium iodide (Sigma), 10 µg/ml RNaseA, 0.05 mM ethylene diamine and 0.2% Triton X-100 tetra-acetic acid for 30 min in the absence of light. For each sample, at least 20,000 cells were acquired on an EPICS Altra flow cytometer (Beckman Coulter, Inc., Brea, CA, USA) and analyzed using Multicycle AV software version 5.0 (Phoenix Flow Systems, San Diego, CA, USA).
For apoptosis detection, cells (2x10 5 ) were collected a nd st a i ne d wit h a n A n nex i n V-phyco er y t h r i n (PE)/7-aminoactinomycin D (AAD) Apoptosis Detection kit (Sigma-Aldrich; Merck Millipore) according to the manufacturer's protocol. Cells were acquired and analyzed as above. Western blotting. Cells were washed with cold PBS and lysed in culture dishes using PhosphoSafe™ extraction reagent (Merck Millipore) containing 1% protease inhibitor cocktail (EDTA-free; Thermo Fisher Scientific, Inc.). Protein concentrations were then determined using Bio-Rad detergent-compatible protein assays (Bio-Rad Laboratories, Inc., Hercules, CA, USA). Proteins (50 µg) were loaded onto 12% SDS-PAGE gels, electrophoresed and transferred onto polyvinylidene difluoride membranes (0.22 µm; Merck Millipore). Membranes were blocked with 5% nonfat milk and incubated with rabbit anti-Bmi-1 monoclonal antibody (1:1,000; catalog no. 2830S; Cell Signaling Technology, Inc., Danvers, MA, USA) and rabbit polyclonal anti-β-actin (1:1,000; catalog no. ab119716; Abcam, Cambridge, MA, USA) for 1.5 h at room temperature. Following washing, membranes were incubated for 1 h at room temperature with a horseradish peroxidase-conjugated mouse anti-rabbit secondary antibody (1:1,000; catalog no. bs-0295M; Bioss Inc., Woburn, MA, USA). Protein bands were visualized using an Enhanced Chemiluminescence reagent (Pierce Biotechnology, Inc., Rockford, IL, USA).
Statistical analysis. Statistical analyses were performed using GraphPad Prism software version 5.0 (GraphPad Software, Inc., La Jolla, CA, USA). Data are presented as the mean ± standard error. The data were subjected to two-tailed Student's t-test. Linear regression analysis was used to investigate the relationship between the expression of miR-203 and Bmi-1. P<0.05 was considered to indicate a statistically significant difference.
Results
miR-203 downregulates Bmi-1 expression by directly targeting the Bmi-1 3'UTR.
Bmi-1 is upregulated significantly in various malignancies including MM, and may be post-transcriptionally regulated by miRNAs. Therefore, Bmi-1 may be regulated by miRNAs in MM. The online miRNA target-prediction tools, TargetScan (www.targetscan.org/vert_71/), PicTar (pictar.mdc-berlin.de/) and miRanda (www.microrna. org/microrna/home.do), were used to predict Bmi-1-targeting miRNAs. The number of potential Bmi-1-targeting miRNAs was 16, 12 and 82 for TargetScan, PicTar and miRanda, respectively. Altogether, a pool of 86 miRNAs that may potentially target Bmi-1 was selected. Of these miRNAs, miR-203 has been reported as a tumor suppressor miRNA inhibiting cellular proliferation by targeting CREB1 mRNA in MM (20) . Therefore, the present study focused on miR-203. To determine whether miR-203 exerts its function by downregulating the expression of Bmi-1 through direct binding to its 3'UTR, full-length fragments of Bmi-1 mRNA 3'UTR (wild-type or mutant) were constructed and inserted immediately downstream of the luciferase reporter gene. For the luciferase assays, the miR-203 mimic was cotransfected with the luciferase 3'UTR constructs into U266 cells and RPMI8226 cells. The results revealed that miR-203 decreased the relative luciferase activity when transfected with wild-type, but not mutant, Bmi-1 3'UTR (P=0.022 and P=0.016 for U266 and RPMI8226 cells, respectively; Fig. 1A ). In accordance with these results, a marked decrease was observed in endogenous Bmi-1 protein (Fig. 1B) and mRNA (P=0.018 and P=0.024 for U266 and RPMI8226 cells, respectively; Fig. 2C and D) . Therefore, the growth-inhibiting effect of miR-203 on MM cells may be due to the arrest of cell cycle progression at the G 1 /S transition.
Ectopic expression of miR-203 promotes MM cell apoptosis.
Annexin V-PE/7-AAD staining was performed to evaluate the effect of miR-203 overexpression on MM cell apoptosis. The percentage of apoptotic U266-control and U266-203 cells was 1.5±0.008 and 36±2.04% (P<0.001), respectively (Fig. 3A) ; the percentage of apoptotic RPMI8226-control and RPMI8226-203 cells was 13.66±0.98 and 30.06±1.65% (P=0.014), respectively (Fig. 3B) . Therefore, ectopic expression of miR-203 may promote MM cell apoptosis by targeting Bmi-1.
miR-203 is downregulated in MM and negatively correlates
with Bmi-1 expression. To determine miR-203 expression levels in bone marrow MNCs from newly diagnosed MM patients and healthy donors, RT-qPCR was performed. miR-203 was significantly downregulated in MM patients compared with healthy controls (P<0.001; Fig. 4A ). Bmi-1 was relatively highly expressed in MM and negatively correlated with miR-203 expression (P= 0.0128; Fig. 4B ). Furthermore, miR-203 expression levels were examined in certain patients following treatment remission and relapse. miR-203 expression increased following remission and declined again following relapse (Fig. 4C) . Taken together, these results demonstrated that the expression levels of miR-203 were downregulated in MM patients, and may be associated with the current disease state. 
Discussion
Bmi-1 was originally described as interacting with c-Myc to initiate lymphoma in mice (1) . Evidence has demonstrated that Bmi-1 is critical for numerous physiological and pathological processes, including hematopoiesis (3), senescence (4), axial patterning (2), regulation of proliferation and maintenance of cancer stem cell self-renewal (5). In addition, evidence has suggested that Bmi-1 is upregulated in various malignancies, including colorectal cancer (6), non-small cell lung cancer (8) , pancreatic cancer (24), breast cancer (25) , prostate cancer (26) and leukemia (7) . Bmi-1 is overexpressed in MM and may regulate cell proliferation and carcinogenesis in vitro and in vivo. Our previous study demonstrated that silencing of Bmi-1 sensitizes MM cells to bortezomib (10) . However, the reasons behind the upregulation of Bmi-1 in MM remain unclear.
miRNAs are post-transcriptional regulators of downstream gene expression, and may function as oncogenes or tumor suppressor genes during tumor development and progression (27) . Previous studies have suggested that Bmi-1 may be post-transcriptionally regulated by miRNAs (11) (12) (13) (14) ; however, whether miRNAs target Bmi-1 in MM remains unclear. In the present study, three miRNA target-prediction tools, TargetScan, PicTar and miRanda, were used to predict all the miRNAs that may target Bmi-1. A total of 86 miRNAs were identified that may target Bmi-1. Of these miRNAs, miR-203 was selected for further investigation. Previous studies have reported that miR-203 is downregulated in MM and CML due to epigenetic silencing, and that CREB1 is a novel target of miR-203 in MM (19, 20) . However, computational analysis indicates that one miRNA may regulate multiple mRNAs. Therefore, more mRNAs than CREB1 may be regulated by miR-203 in MM. The present study identified Bmi-1 as a direct downstream target of miR-203 in MM cells. A potential miR-203 target site was identified in the Bmi-1 3'UTR. Following cotransfection with wild-type 3'UTR, miR-203 decreased the relative luciferase activity. However, when the potential target site was mutated, luciferase activity was unaffected. In accordance with these results, endogenous Bmi-1 protein and mRNA expression levels were demonstrated to be downregulated by miR-203 in MM cells.
If miR-203 functions as a tumor suppressor in MM, restoration of miR-203 expression in MM cells may inhibit proliferation and/or promote apoptosis. The present study demonstrated that ectopic expression of miR-203 in MM cells led to a significant inhibition of proliferation and the arrest of cell cycle progression at the G 1 /S transition. In addition, the present study suggested that miR-203 re-expression may promote MM cell apoptosis by targeting Bmi-1. Taken together, these results confirm miR-203 as a tumor suppressor in MM. Furthermore, the expression levels of miR-203 and Bmi-1 in MM patient and healthy control bone marrow samples were detected. miR-203 was significantly downregulated in MM; Bmi-1 was relatively abundant in MM and negatively correlated with miR-203 expression. In certain clinical circumstances, miRNA profiling may be superior to mRNA profiling to classify tumor subtypes and predict prognosis. The present study demonstrated that miR-203 expression may indicate current disease status.
In conclusion, the results of the present study demonstrated, to the best of our knowledge for the first time, that miR-203 may target Bmi-1 in MM, inhibit MM cell growth and regulate G 1 /S transition. These results suggested that miR-203 has tumor suppressor properties and therefore potential therapeutic application in MM.
